Rasburicase in Tumor Lysis Syndrome

Registry ID

EUCTR2014-003989-24

Source registry

EUCTR

Phase

PHASE4

Sponsor

Sanofi

Last update

2026-08-16

Conditions

• Hyperuricemia

Summary

The purpose of this study is to determine whether rasburicase is effective and safety in correcting hyperuricemia.

Related clinical trials

• Evaluation of the Effect of Hyperuricemia on Alveolar Bone Loss
• Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support Tools in the Management of Patients With "Four Highs" (Hypertension, Hyperglycemia, Hyperlipidemia, Hyperuricemia)
• A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease
• A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
• This Study is to Estimate the Efficacy of Hemodialysis Alone for Uric Acid Clearance in Patients on Hemodialysis. In Order to Evaluate the Need of Adjuvant Uric Acid Lowering Therapy
• Effects of Fibres Combined With Probiotics on Uric Acid in an ex Vivo Fermentation Model

View on source registry